IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 10087248 B1

PDFFull Text
Date of Patent:
Oct. 02, 2018

Filed:

May. 22, 2014

Anti-tnf-α/cxcl10 double-targeting antibody and use thereof

Applicant:

Metabolic Engineering Laboratories Co., Ltd., Seoul, KR;

Inventors:

Heun-Soo Kang, Gwacheon-si, KR;

So-Hyun Park, Namyangju-si, KR;

Yeong Wook Song, Seoul, KR;

Ki Chul Shin, Seoul, KR;

Eun Young Lee, Seoul, KR;

Eun Bong Lee, Seoul, KR;

Young Woo Park, Daejeon, KR;

Bum-Chan Park, Daejeon, KR;

Dong Hee Lee, Daejeon, KR;

Dong Jin Kim, Daejeon, KR;

Seon Ha Yun, Daejeon, KR;

Ke Se Lee, Daejeon, KR;

Hyun Ju Lee, Daejeon, KR;

Kyung Jin Kim, Daejeon, KR;

Hee Chan Kim, Daejeon, KR;

Seok Ho Yoo, Daejeon, KR;

Myeoung Hee Jang, Daejeon, KR;

Seil Jang, Daejeon, KR;

Assignee:

METABOLIC ENGINEERING LABORATORIES CO., LTD., Seoul, KR;

Attorneys:

Don D. Cha

Hamilton DeSanctis & Cha, LLP

Primary Examiner:

Christine J Saoud

Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/24 (2006.01); C12N 5/10 (2006.01); C07K 16/46 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/241 (2013.01); C07K 16/24 (2013.01); C07K 16/46 (2013.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/64 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

The present invention relates to a TNF-α (tumor necrosis factor-alpha)/CXCL-10 (C-X-C motif chemokine 10) double targeting antibody based on the IgG format. Specifically, it was verified that an antibody, in which scFv having a heavy chain variable domain and a light chain variable domain of the CXCL10 specific antibody links to the C-terminus of the heavy chain constant domain of the TNF-α specific antibody, is a bispecific antibody that effectively binds to both TNF-α and CXCL10, and thus the antibody can be useful as a double targeting antibody capable of identifying TNF-α/CXCL10. A composition of the present invention comprises a TNF-α/CXCL-10 double targeting antibody which effectively binds to both TNF-α and CXCL10. The double targeting antibody of the present invention has excellent TNF-α inhibitory activity and osteoclast differentiation inhibitory activity compared with the TNF-α or CXCL10 single targeting antibody. The composition of the present invention can be used in preventing or treating immunological disease.

Find Patent Forward Citations

Loading…